The association of stress level with the central serous chorioretinopathy development

Abstract

Background. The impact of stress on the central serous chorioretinopathy development has been studied in a small number of studies, and the results are conflicting.

Aim. To assess the association of the level of individual stress with the central serous chorioretinopathy development.

Material and methods. A cross-sectional study based on a survey of 110 patients with central serous chorioretino­pathy (the main group) and 110 individuals without central serous chorioretinopathy was conducted. The stress level was assessed on the Perceived Stress Scale. Quantitative and categorical data between the groups were compared. Comparison of groups by quantitative indicator was performed using the Mann–Whitney U-test, and by categorical indicator — using the odds ratio and its 95% confidence intervals.

Results. The groups of respondents were comparable according to the main demographic indicators. The median total score for the “Overstrain” subscale in the central serous chorioretinopathy group was 12 points (Q25%–Q75% 9.25–14 points), in the control group — 10 points (Q25%–Q75% 7–12 points; p=0.0002). The median total score for the “Stress Response” subscale in the central serous chorioretinopathy group was 7 points (Q25%–Q75% 5–8 points), in the control group it was 4 points (Q25%–Q75% 3–7 points; p=0.000003). In the group with central serous chorioretinopathy, compared with the control group, the proportion of people with moderate stress level was higher (74.5% vs. 53.6%; odds ratio 2.53, 95% confidence interval 1.43÷4.48) and the proportion of people with low stress level was lower (19.1% vs. 45.5%; odds ratio 0.28, 95% confidence interval 0.15÷0.52).

Conclusion. The study demonstrated the association of stress with the development of central serous chorioretinopathy.

Keywords

psychogenic risk factors / stress / central serous chorioretinopathy

References

[1] Wong KH, Lau KP, Chhablani J, Tao Y, Li Q, Wong IY. Central serous chorioretinopathy: what we have learnt so far. Acta Ophthalmol. 2016;94(4):321–325. DOI: 10.1111/aos.12779.

[2] Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121(5):1067–1072. DOI: 10.1016/j.ophtha.2013.11.020.

[3] Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, Merriam JC, Barbazetto I, Slakter JS, Chang S, Munch IC, Drack AV, Hernandez J, Yzer S, Merriam JE, Linneberg A, Larsen M, Yannuzzi LA, Mullins RF, Allikmets R. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Human Mutation. 2014;35(7):859–867. DOI: 10.1002/humu.22551.

[4] De Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JEE, Hoyng CB, den Hollander AI, Boon CJF. Chronic central serous chorioretinopathy is associated with genetic variants implica­ted in age-related macular degeneration. Ophthalmology. 2015;122(3):562–570. DOI: 10.1016/j.ophtha.2014.09.026.

[5] Eom Y, Oh J, Kim S-W, Huh K. Systemic factors associated with central serous chorioretinopathy in Koreans. Korean J Ophthalmol. 2012;26(4):260. DOI: 10.3341/kjo.2012.26.4.260.

[6] Tsai D-C, Huang C-C, Chen S-J, Chou P, Chung C-M, Chan W-L, Huang P-H, Chen T-J, Lin S-J, Chen J-W, Leu H-B. Central serous chorioretinopathy and risk of ischae­mic stroke: a population-based cohort study. Br J Ophthalmol. 2012;96(12):1484–1488. DOI: 10.1136/bjophthalmol-2012-301810.

[7] Horniker E. Su di unaforma di retinitecentrale di originevasoneurotica. Ann Ottalmol. 1927;55:830–840.

[8] Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol. 1997;81(11):962–964. DOI: 10.1136/bjo.81.11.962.

[9] Kapetanios AD, Donati G, Bouzas E, Mastorakos G, Pournaras CJ. Choriorétinopathie seéeuse centrale et hypercortisoleéie endogène. Klin Monatsbl Augenheilkd. 1998;212(05):343–344. DOI: 10.1055/s-2008-1034901.

[10] Zakir S, Shukla M, Simi Z, Ahmad J, Sajid M. Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy. Indian J Ophthalmol. 2009;57(6):419. DOI: 10.4103/0301-4738.57143.

[11] Chatziralli I, Kabanarou SA, Parikakis E, Chatzirallis A, Xirou T, Mitropoulos P. Risk factors for central serous chorioretinopathy: Multivariate approach in a case-control study. Curr Eye Res. 2017;42(7):1069–1073. DOI: 10.1080/02713683.2016.1276196.

[12] Conrad R, Geiser F, Kleiman A, Zur B, Karpa­witz-Godt A. Temperament and character personality profile and illness-related stress in central serous chorioretino­pathy. Scientific World Journal. 2014:631687. DOI: 10.1155/2014/631687.

[13] Mansour AM, Koaik M, Lima LH, Casella AMB, Uwaydat SH, Shahin M, Tamim H, Sanchez-Ruiz M-J, Mansour HA, Dodwell D. Physiologic and psychologic risk factors in central serous chorioretinopathy. Ophthalmol Retina. 2017;1(6):497–507. DOI: 10.1016/j.oret.2017.02.009.

[14] Bousquet E, Dhundass M, Lehmann M, Rothschild P-R, Bayon V, Leger D, Bergin C, Dirani A, Beydoun T, Behar-Cohen F. Shift work: A risk factor for central serous chorioretinopathy. Am J Ophthalmol. 2016;165:23–28. DOI: 10.1016/j.ajo.2016.02.012.

[15] Bazzazi N, Ahmadpanah M, Akbarzadeh S, Seif Rabiei MA, Holsboer-Trachsler E, Brand S. In patients suffering from idiopathic central serous chorioretinopathy, anxiety scores are higher than in healthy controls, but do not vary according to sex or repeated central serous chorioretinopathy. Neuropsychiatr Dis Treat. 2015;11:1131–1136. DOI: 10.2147/NDT.S83216.

[16] Matet A, Daruich A, Zola M, Behar-Cohen F. Risk factors for recurrences of central serous chorioretinopathy. Retina. 2018;38(7):1403–1414. DOI: 10.1097/IAE.0000000000001729.

[17] Kelsey JL, editor. Methods in observational epidemio­logy. 2nd ed. New York: Oxford University Press; 1996. 432 p.

[18] Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385. DOI: 10.2307/2136404.

[19] Ababkov VA, Barisnikova K, Vorontzova-Wenger OV, Gorbunov IA, Kapranova SV, Pologaeva EA, Stuklov KA. Validation of the Russian version of the questionnaire “Scale of perceived stress-10.” Vestnik SPbSU. Series 16. Psycho­logy. Education. 2016;(2):6–15. (In Russ.) DOI: 10.21638/11701/spbu16.2016.202.

[20] Абабков В.А., Барышникова К., Воронцова-Венгер О.В., Горбунов И.А., Капранова С.В., Пологаева Е.А., Стуклов К.А. Валидизация русскоязычной версии опросника «шкала воспринимаемого стресса-10». Вестник Санкт-Петербургского университета. Серия 16. Психология. Педагогика. 2016;(2):6–15. DOI: 10.21638/11701/spbu16.2016.202.

[21] Аgliullin DR, Khasanova GR, Abdulaeva EA, Agliullina ST, Amirov AN, Kuskov AN, Kim AA, Rascheskov AYu, Lipinskiy DA. The incidence of central serous chorioretinopathy in the population of Kazan: Results of a retrospective epidemiological analysis for 2009–2018. Pacific Medical Journal. 2020;(3):30–33. (In Russ.) DOI: 10.34215/1609-1175-2020-3-30-33.

[22] Аглиуллин Д.Р., Хасанова Г.Р., Абдулаева Э.А., Аглиуллина С.Т., Амиров А.Н., Кусков А.Н., Ким А.А., Расчёсков А.Ю., Липинский Д.А. Заболеваемость центральной серозной хориоретинопатией населения г. Казани: результаты ретроспективного эпидемиологического анализа за 2009–2018 гг. Тихоокеанский медицинский журнал. 2020;(3):30–33. DOI: 10.34215/1609-1175-2020-3-30-33.

[23] Khasanova GR, Hakimov NM, Аgliullin DR, Abdulaeva EA. Risk factors for central serous chorioretinopathy. Systema­tic review and meta-analysis. Meditsina. 2020;8(1):102–124. (In Russ.) DOI: 10.29234/2308-9113-2020-8-1-102-124.

[24] Хасанова Г.Р., Хакимов Н.М., Аглиуллин Д.Р., Абдулаева Э.А. Факторы риска развития центральной серозной хориоретинопатии. Систематический обзор и метаанализ. Медицина. 2020;8(1):102–124. DOI: 10.29234/2308-9113-2020-8-1-102-124.

[25] Kaye R, Chandra S, Sheth J, Boon CJF, Siva­prasad S, Lotery A. Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res. 2020;79:100865. DOI: 10.1016/j.preteyeres.2020.100865.

RIGHTS & PERMISSIONS

Eco-Vector